The losartan renal protection study - Rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)

Barry M. Brenner, Mark E. Cooper, Dick De Zeeuw, Jean Pierre Grunfeld, William F. Keane, Kiyoshi Kurokawa, Janet B. McGill, William E. Mitch, Hans Henrik Parving, Guiseppe Remuzzi, Arthur B. Ribeiro, Mark D. Schluchter, Duane Snavely, Zhongxin Zhang, Roger Simpson, Denise Ramjit, Shahnaz Shahinfar

Research output: Contribution to journalArticle

Abstract

The RENAAL Study is a double-blind, placebo-controlled trial to evaluate the renal protective effects of losartan in Type 2 diabetic patients with nephropathy. The study has enrolled 1513 patients and is expected to continue for 3.5 years after the last patient has been entered. Eligible patients must have a urinary albumin:creatinine ratio of at least 300 mg/g and serum creatinine between 1.3 to 3.0 mg/dL. Eligible hypertensive or normotensive patients are randomised to receive either losartan or placebo, in addition to their existing antihypertensive therapy. Medications that block angiotensin production or action, are excluded. The primary endpoint is a composite of the time to first event of doubling of serum creatinine, end-stage renal disease, or death; secondary endpoints include cardiovascular events, progression of renal disease, and changes in proteinuria; tertiary endpoints include quality of life, healthcare resource utilisation, and amputations. Patients include Caucasians (48.6%), Blacks (15.2%), Asians (16.7%), and Hispanics (18.2%). Baseline urinary albumin:creatinine ratio and serum creatinine levels average 1867 mg/g and 1.9 mg/dL, respectively. Mean systolic and diastolic blood pressures are 153 and 82 mmHg, respectively. RENAAL will document whether blockade of the AII receptor with losartan produces clinical benefits in patients with Type 2 diabetes and nephropathy.

Original languageEnglish
Pages (from-to)328-335
Number of pages8
JournalJRAAS - Journal of the Renin-Angiotensin-Aldosterone System
Volume1
Issue number4
Publication statusPublished - Dec 2000

Keywords

  • Angiotensin II receptor antagonist
  • Creatinine clearance
  • End-stage renal disease
  • Losartan
  • Non-insulin dependent diabetes mellitus
  • Proteinuria

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine

Fingerprint Dive into the research topics of 'The losartan renal protection study - Rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)'. Together they form a unique fingerprint.

  • Cite this

    Brenner, B. M., Cooper, M. E., De Zeeuw, D., Grunfeld, J. P., Keane, W. F., Kurokawa, K., McGill, J. B., Mitch, W. E., Parving, H. H., Remuzzi, G., Ribeiro, A. B., Schluchter, M. D., Snavely, D., Zhang, Z., Simpson, R., Ramjit, D., & Shahinfar, S. (2000). The losartan renal protection study - Rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 1(4), 328-335.